Tier C · Early / limited human evidence
AOD-9604
An elegant idea—separating fat-metabolism signaling from full growth hormone—that did not become an approved obesity drug.
Why researchers care
Potential human relevance
- Designed to study the lipolytic region of growth hormone without full GH activity
- Human development generated useful safety and tolerability data
- Did not produce the feared classic full-length GH adverse-effect pattern in published safety work
What the human evidence says
Evidence, not extrapolation
AOD-9604 went through human development, but weight-loss efficacy was not strong enough to establish it as an approved obesity treatment.
How to think about it
The Yooper Peptides take
Negative or incomplete development is still valuable science. A peptide can be biologically plausible and well tolerated without producing a clinically meaningful outcome.
Primary / authoritative reading